




University of  
Nottingham

UK | CHINA | MALAYSIA



ISRCTN97695350

A large, glowing blue and green Earth seen from space, centered in the background.

**TRANEXAMIC ACID  
FOR INTRACEREBRAL  
HAEMORRHAGE:  
TICH-3 TRIAL  
INVESTIGATOR  
MEETING**


Professor Nikola Sprigg

On behalf TICH-3 Trial Team

13<sup>th</sup> September 2022



# Agenda



1. Recruitment update
2. Recruiting experience – University Hospital of North Durham and Charing Cross Hospital
3. Uploading documents to TICH-3 website
4. Co-enrolment
5. Haematoma volume estimation
6. Thank you
7. Questions?



# Recruitment Update



Site Status	Number
Sites open to recruitment	27
Recruited ( <i>27 participants in total</i> )	12
Not – recruited	15
In set up	30
Initial feasibility assessments	9
Declined for now (capacity issues)	11
Withdrawn	7



# Recruiting Experience

Colleagues from University Hospital of North Durham and Charing Cross Hospital are going to share their experience of recruiting into the TICH-3 trial

**Is there anyone else on the call who would like to share?**



# Recruiting Experience - Feedback

## North Durham (Ami Wilkinson):

Lovely trial that has a pragmatic randomisation process. The consent is simple. They are working on their on-call Consultant availability process. They enjoy being part of the trial.

## Charing Cross/Imperial College (Sheila Mashate):

Recruited 2 patients from out of hours. Staff availability who are on the delegation log during these times can be challenging. They had a couple of patients who had a history of seizures which they were cautious of and therefore were excluded based on that.

Regarding Cannula checks, calculating the volume was not always straight forward and they had to discuss with Neurologists to calculate.

The verbal consent helps a lot and the QR code is simple and useful.




# Uploading Documents to TICH-3 Website




## Document uploads


Please upload the following documents to the secure vault site via the TICH-3 website as soon as possible after enrolment:

- Baseline CT/MRI Scan reports to confirm eligibility **(MUST be anonymised)**
- Drug charts to confirm correct pack number used **(MUST be anonymised)**
- Consent forms to confirm consent obtained **(DO NOT anonymise consent forms)**

 Identifying information **MUST NOT** be entered into this pseudonymised database for TICH-3. You can use the secure vault (see below) to provide us with the participant's contact details and other identifying information, which will be encrypted and stored separately.

 You can also use the secure vault to upload required documents for the selected participant. Please indicate the document type below, or use the 'Multiple document types' option (if you have a mix of documents in one file). If your file isn't a PDF or image, please 'print' it to a PDF first.

Please choose a data type to access the secure vault

  (\*) applicable type only

## CT scan images

To be uploaded **(MUST be anonymised)** to the TICH-3 website, not the secure vault.

- The scans must include the date/time present at a minimum
- It's also preferable to retain some pseudonymised data - such as date of birth and sex - to allow the system to ensure that the correct scans are being uploaded.

If scans cannot be uploaded to the TICH-3 website please post **(MUST be anonymised)** to us on a CD.

To anonymise please block out the patient's name and add their participant ID number to the document



# Co-enrolment with MAPS-2 Trial - Synopsis



## **MAPS-2:** The Metoclopramide for Avoiding Pneumonia after Stroke Trial




- **Setting:** Emergency departments and stroke units of 60-90+ NHS hospitals in the United Kingdom.
- **Population:** 2100 participants with post-stroke dysphagia,  $\leq 9$  hours of symptom onset. Patients with either ischaemic or haemorrhagic strokes are eligible.
- **Intervention:** Metoclopramide, administered via slow IV injection or nasogastric tube, 10mg/2ml three times per day for 14 days (or discharge).
- **Comparison:** Sodium chloride 0.9% solution, administered via slow IV injection or nasogastric tube, 2ml three times a day for 14 days (or discharge).
- **Outcome:** Mortality by 6 months (*primary*). Pneumonia diagnosis and neurological recover at day 14; long-term disability outcome at 6 months; cost effectiveness of metoclopramide (*secondary*).
- **Design:** A large multicentre phase III participant-blinded parallel two-arm randomized placebo-controlled trial (with an internal pilot running for the initial nine months).
- **Funder:** UK NIHR HTA
- **Email:** MAPS-2@nottingham.ac.uk

**Website:** <https://stroke.nottingham.ac.uk/maps-2/>



# Co-enrolment with MAPS-2 Trial




- Co-enrolment between TICH-3 and MAPS-2 has been agreed, as both are sponsored by University of Nottingham there does not need to be a contract in place at site for co-enrolment to occur
- Metoclopramide is considered safe
- Enrolment within 9 hours of symptom onset

**Any questions?**





# Co-enrolment with Trident and ENRICH-AF



- Co-enrolment between TICH-3 and TRIDENT has now been agreed
  - As both trials are with different sponsors there is an agreement in place confirming both sponsors approval of co-enrolment
  - If you are taking part in TRIDENT please let us know so your site (PI and R&I) can document they agree to co-enrolment at your site.
- 
- Co-enrolment between TICH-3 and ENRICH-AF is in the process of being formalised....




**Any questions?**




---

## Haematoma Volume Estimation



# ABC/2 – ABBREVIATIONS EXPLAINED

- A: the maximal length of the largest slice of hematoma (cm);
- B: the maximum width perpendicular to A determined on the slice of maximal area;
- C: the height of hematoma (number of slices with haemorrhage multiplied by slice thickness (cm))



# TICH-3 trial Tranexamic acid for IntraCerebral Haemorrhage 3

ISRCTN 97695350

Room S/D2123, Stroke Trials Unit  
School of Medicine, University of Nottingham  
Queen's Medical Centre, Derby Road  
Nottingham NG7 2UH, United Kingdom  
TICH-3 trial office <tich-3@nottingham.ac.uk>

## Haematoma volume calculator

Investigator: **Chaamanti Sivakumar**

Log out

« [Back to start page](#)

### Estimated volume of largest haematoma

[View guide](#)

Maximum haematoma length 'A'  
(up to 4 decimal places)  cm

Maximum haematoma width 'B'  
(up to 4 decimal places)  cm

Number of slices where haematoma visible  slices

Scan slice thickness  mm

**Please enter the individual components and then  
the calculated volume will be shown.**

[Switch to mobile site](#)

MD+  
CALC



Search "QT interval" or "QT" or "EKG"



## ABC/2 Formula for Intracerebral Hemorrhage Volume ☆

Predicts volume of intracranial hemorrhage from CT measurements.

### INSTRUCTIONS

Measure length and width on the CT slice with the largest area of hemorrhage.  
NOTE: CT slices are typically measured in mm, not cm.

When to Use ▾

Pearls/Pitfalls ▾

Why Use ▾

Hemorrhage Shape

Round or Ellipsoid

Irregular, Separated, or Multinodular

Hemorrhage Length

cm

Hemorrhage Width

cm

Number of CT Slices

Slice with ≥75% Area of Hemorrhage:  
Counts as 1 slice; Slice with 25-75%  
Area of Hemorrhage: Counts as 0.5  
slices; Slice with <25% Area of  
Hemorrhage: Counts as 0 slices

slices


CT Slice Thickness


mm

## Result:


Please fill out required fields.

# Worked Example 1





C = 16 slices




ABC/2


$$\frac{3.7 \times 2.4 \times (16 \times 0.5)}{2}$$

$$= 35.52\text{cm}^3$$




WORKED  
EXAMPLE  
2






Basal Ganglia ICH

Concomitant IVH



C – Slices 7



# ABC/2

## TICH-3 trial Tranexamic acid for IntraCerebral Haemorrhage 3

ISRCTN 97695350

Room S/D2123, Stroke Trials Unit  
School of Medicine, University of Nottingham  
Queen's Medical Centre, Derby Road  
Nottingham NG7 2UH, United Kingdom  
TICH-3 trial office <tich-3@nottingham.ac.uk>

### Haematoma volume calculator

#### Estimated volume of largest haematoma

[View guide](#)

Maximum haematoma length 'A'  
(up to 4 decimal places)  cm

Maximum haematoma width 'B'  
(up to 4 decimal places)  cm

Number of slices where haematoma visible  slices

Scan slice thickness  
(up to 3 decimal places)  mm


---

**Calculated volume (ABC/2) = 11.7687 cm<sup>3</sup>**


---

**Please enter the individual components and then  
the calculated volume will be shown.**

# Worked Example 3



C – Slices 25



# TICH-3 trial Tranexamic acid for IntraCerebral Haemorrhage 3

Room S/D2123, Stroke Trials Unit  
School of Medicine, University of Nottingham  
Queen's Medical Centre, Derby Road  
Nottingham NG7 2UH, United Kingdom  
TICH-3 trial office <tich-3@nottingham.ac.uk>

ISRCTN 97695350

## Haematoma volume calculator

Investigator: **Chaamanti Sivakumar**

Log out

« [Back to start page](#)

### Estimated volume of largest haematoma

[View guide](#)

Maximum haematoma length 'A'  
(up to 4 decimal places)  cm

Maximum haematoma width 'B'  
(up to 4 decimal places)  cm

Number of slices where haematoma visible  slices

Scan slice thickness  
(up to 3 decimal places)  mm

---

**Calculated volume (ABC/2) = 177 cm<sup>3</sup>**

---

**Please enter the individual components and then  
the calculated volume will be shown.**





# Q & A following Hematoma Volume slide



- (Issue with presentation: Animation of imaging did not function as desired)
- Presented by Chaamanti Sivakumar
  
- **Q: Who can complete haematoma volume (HV) estimation?**  
A: Anyone can complete the HV estimation, but the treating physician has final decision on whether to enrol
  
- **Q: Is 60ml an absolute cut off for inclusion?**
- A: HV calculation is an estimate only, some recruits with  $HV > 60$  have been enrolled whereas as some patients with  $HV < 60$  have not been recruited, it depends on various factors including location of bleed, GCS, NIHSS etc. Should seek Physician advice if unsure.



# Thank You




The TICH-3 trial would not be possible without the support of our investigators, thank you very much to everyone that has joined us thus far!



University of  
Nottingham

UK | CHINA | MALAYSIA



**Any questions?**



# Q & A during the session



- **Q: Can we enroll if patient on warfarin?**

A: To be excluded needs to be treatment dose anticoagulation

- **Q: Regarding the co-enrollment, why can't we use one consent form?**

A: They are platform trials and unfortunately cannot share the same consent form

- **Q: Regarding PRESTIGE**

A: PRESTIGE team decision not to co-enroll as they are closing so wouldn't get a contract executed in time.

- **Q: Process regarding CT/MRI upload**

A: Needs to be anonymized but with date & time of scan and DOB visible. So that the system can complete a quality check that it is being uploaded for the right person.

- **Q: Can Nurses consent?**

A: If appropriately trained in taking informed consent for drug trials – yes

- **Q: Why there is no witness box on the consent form?**

A: This was taken off and there are currently no plans to amend the consent forms but this can be revisited in the future.

- **Q: Can we recruit if someone has a history of seizure?**

A: Yes, the exception being active seizures. The decision to enroll lies with the treating clinician.